NEW YORK, June 2 (GenomeWeb News) - Dutch biotech Agendia has closed a third round of financing with the Van Herk Group and Gilde Healthcare, the company said today. It did not disclose the amount of the financing.
The cash will help Agendia develop its microarray-based late stage products into diagnostics for breast cancer and other cancer types. It will also help the company to globally market its CupPrint and MammaPrint prognostic breast cancer tests.
Agendia CEO Bernhard Sixt said the company is expanding its EU presence and is in "advanced" talks with the FDA to enter the US market.
Van Herk Group, Gilde Healthcare, AXA Private Equity Venture Funds, Global Life Sciences Ventures, and the Netherlands Cancer Institute are current investors.